Permira completed the acquisition of Ergomed for £703m.

Permira, a British global investment firm specialised in buyout, growth equity and credit funds, completed the acquisition of Ergomed, a pharmaceutical services company that provides a wide range of services to the biotechnology, pharmaceutical, and medical device industries, for £703m. "We are delighted to be announcing this recommended cash acquisition of Ergomed, a high quality, medic-led and fast growing pharma services platform. We look forward to partnering with the Ergomed management team in accelerating Ergomed's growth and fulfilling its vision of becoming the leading pharmacovigilance and rare disease clinical development partner to pharma and biotech clients to safely commercialise complex and often life-saving therapies for patients. Miro and his team have built a very strong foundation and as we look to the next phase of Ergomed's growth, we will continue to support commercial expansion, new capabilities and technological innovation, via investments into the business as well as transformational M&A," Silvia Oteri, Permira Partner and Head of Healthcare.